BOLLI, NICCOLO'
BOLLI, NICCOLO'
Dipartimento di Oncologia ed Emato-Oncologia
Whole-exome sequencing is feasible on a fresh-frozen skin sample of intravascular large B cell lymphoma
2024 F. Bagnoli, G. Pini, B. Ziccheddu, A. Bonometti, S. Alberti-Violetti, L. Venegoni, G. Isimbaldi, M.C. Da Vià, A. Ferrari, L. Baldini, A. Neri, F. Onida, N. Bolli, E. Berti
Unraveling the Neurological Complexity of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes Syndrome: A Report of a Challenging Case of a Young Woman and Cutting-Edge Advancements in the Field
2023 G. Furciniti, G. Casalino, F.M. Lo Russo, N. Bolli, M. Meneri, G.P. Comi, S.P. Corti, D. Velardo
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
2023 N. Platonova, E. Lazzari, M. Colombo, M. Falleni, D. Tosi, D. Giannandrea, V. Citro, L. Casati, D. Ronchetti, N. Bolli, A. Neri, F. Torricelli, L.A. Crews, C.H.M. Jamieson, R. Chiaramonte
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
2023 E. Sauta, M. Robin, M. Bersanelli, E. Travaglino, M. Meggendorfer, L. Zhao, J.C. Caballero Berrocal, C. Sala, G. Maggioni, M. Bernardi, C. Di Grazia, L. Vago, G. Rivoli, L. Borin, S. D'Amico, C.A. Tentori, M. Ubezio, A. Campagna, A. Russo, D. Mannina, L. Lanino, P. Chiusolo, L. Giaccone, M.T. Voso, M. Riva, E.N. Oliva, M. Zampini, E. Riva, O. Nibourel, M. Bicchieri, N. Bolli, A. Rambaldi, F. Passamonti, V. Savevski, A. Santoro, U. Germing, S. Kordasti, V. Santini, M. Diez-Campelo, G. Sanz, F. Sole, W. Kern, U. Platzbecker, L. Ades, P. Fenaux, T. Haferlach, G. Castellani, M.G. Della Porta
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
2023 E. Taiana, C. Bandini, V.K. Favasuli, D. Ronchetti, I. Silvestris, N. Puccio, K. Todoerti, S. Erratico, D. Giannandrea, N. Bolli, N. Amodio, A. Ciarrocchi, R. Chiaramonte, Y. Torrente, R. Piva, A. Neri
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort
2023 D. Cattaneo, C. Bucelli, A. Marchetti, M. Lionetti, E. Fermo, V. Bellani, C. De Magistris, A. Maeda, A. Marella, M. Primignani, D. Consonni, U. Gianelli, A. Neri, L. Baldini, N. Bolli, A. Iurlo
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2023 L. Haertle, S. Barrio, U. Munawar, S. Han, X. Zhou, M. Simicek, C. Vogt, M. Truger, R.A. Fernandez, M. Steinhardt, J. Weingart, R. Snaurova, S. Nerreter, E. Teufel, A. Garitano-Trojaola, M. Da Via, Y. Ruiz-Heredia, A. Rosenwald, N. Bolli, R. Hajek, P. Raab, M.S. Raab, N. Weinhold, C. Haferlach, T. Haaf, J. Martinez-Lopez, H. Einsele, L. Rasche, K.M. Kortüm
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
2023 M. Moscvin, C.I. Liacos, T. Chen, F. Theodorakakou, D. Fotiou, S. Hossain, S. Rowell, H. Leblebjian, E. Regan, P. Czarnecki, F. Bagnoli, N. Bolli, P. Richardson, H.G. Rennke, M.A. Dimopoulos, E. Kastritis, G. Bianchi
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification
2023 V.K. Favasuli, D. Ronchetti, I. Silvestris, N. Puccio, G. Fabbiano, V. Traini, K. Todoerti, S. Erratico, A. Ciarrocchi, V. Fragliasso, D. Giannandrea, F. Tumiatti, R. Chiaramonte, Y. Torrente, P. Finelli, E. Morelli, N.C. Munshi, N. Bolli, A. Neri, E. Taìana
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
2023 B. Diamond, B. Ziccheddu, K. Maclachlan, J. Taylor, E. Boyle, J.A. Ossa, J. Jahn, M. Affer, T.M. Totiger, D. Coffey, N. Chandhok, J. Watts, L. Cimmino, S.X. Lu, N. Bolli, K. Bolton, H. Landau, J.H. Park, K. Ganesh, A. Mcpherson, M.A. Sekeres, A. Lesokhin, D.J. Chung, Y. Zhang, C. Ho, M. Roshal, J. Tyner, S. Nimer, E. Papaemmanuil, S. Usmani, G. Morgan, O. Landgren, F. Maura
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
2022 C. Botta, E. Gigliotta, B. Paiva, R. Anselmo, M. Santoro, P.R. Otero, M. Carlisi, C. Conticello, A. Romano, A.G. Solimando, C. Cerchione, M.D. Vià, N. Bolli, P. Correale, F. Di Raimondo, M. Gentile, J. San Miguel, S. Siragusa
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
2022 M.C. Da Vià, M. Lionetti, A. Marella, A. Matera, E. Travaglino, E. Signaroldi, A.A. Galbussera, U. Lucca, S. Mandelli, E. Riva, M. Tettamanti, L. Pettine, A. Pompa, L. Baldini, A. Neri, M.G. Della Porta, N. Bolli
Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine
2022 M. Manzoni, A. Bosi, S. Fabris, M. Lionetti, S. Salerio, A.C. Migliorini, F. Cavallaro, K. Barbullushi, N. Rampi, V. Montefusco, M.G. Alessio, A. Neri, L. Baldini, M. Sciumè, E. Tagliaferri, N. Fracchiolla, N. Bolli
The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach
2022 B. Oben, C. Cosemans, E. Geerdens, L. Linsen, K. Vanhees, B. Maes, K. Theunissen, B. Cruys, M. Lionetti, I. Arijs, N. Bolli, G. Froyen, J. Rummens
Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
2022 D. Ronchetti, V.K. Favasuli, I. Silvestris, K. Todoerti, F. Torricelli, N. Bolli, A. Ciarrocchi, E. Taiana, A. Neri
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma
2022 A. Matera, A. Marella, A. Maeda, M.C. Da Via, F. Lazzaroni, S. Fabris, S. Pioggia, L. Porretti, F. Colombo, F. Torricelli, A. Neri, E. Taiana, G. Fabbiano, V. Traini, E. Genuardi, D. Drandi, N. Bolli, M. Lionetti
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring {\textquotedblleft}Multiple Myelomas{\textquotedblright}
2022 A. Giovanni Solimando, M.C. DA VIA', N. Bolli, T. Steinbrunn
Response to SARS-CoV-2 vaccination and antibodies persistence in multiple myeloma patients
2022 L. Pettine, M. Bortolotti, B. Fattizzo, M.C. Da Vià, D. Consonni, A. Pompa, N. Bolli, L. Baldini
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
2021 K.H. Maclachlan, E.H. Rustad, A. Derkach, B. Zheng-Lin, V. Yellapantula, B. Diamond, M. Hultcrantz, B. Ziccheddu, E.M. Boyle, P. Blaney, N. Bolli, Y. Zhang, A. Dogan, A.M. Lesokhin, G.J. Morgan, O. Landgren, F. Maura
Cereblon enhancer methylation and IMiD resistance in multiple myeloma
2021 L. Haertle, S. Barrio, U. Munawar, S. Han, X. Zhou, C. Vogt, R.A. Fernandez, M. Bittrich, Y. Ruiz-Heredia, M.C. Da Via, J. Zovko, A. Garitano-Trojaola, N. Bolli, A. Ruckdeschel, T. Stuhmer, M. Chatterjee, M. Kull, J. Kronke, X. Agirre, J.I. Martin-Subero, P. Raab, H. Einsele, L. Rasche, J. Martinez-Lopez, T. Haaf, K.M. Kortum